Skip to content

Vertex Pharmaceuticals VRTX Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin344.9%+0.2pp344.7%-0.9pp344.5%-2.1pp344.4%-4.0pp344.7%-5.1pp
Returns
Return on invested capital103.9%+112pp71.8%+44.5pp46.9%-13.0pp20%-69.2pp-8.5%-128pp
Efficiency
Asset turnover+0.1×0.0×0.0×0.0×0.0×
Liquidity
Current ratio10.8×+0.5×10.4×-0.8×10.2×-2.3×10.3×-3.8×10.3×-5.4×
Leverage
Debt-to-equity0.4×0.0×0.4×+0.1×0.4×+0.1×0.4×+0.2×0.4×+0.2×
Net debt / EBITDA-3×
Per Share
Book value per share$281.46+15.2%$269.49+7.0%$260.77+2.0%$253.43-2.2%$244.33-6.5%
Valuation
Market capitalization$444.5B-5.3%$455.56B+0.6%$444.24B-2.1%$463.87B+9.5%$469.26B+19.3%
Price / sales37.6×-6.1×39.5×-3.5×39.3×-4.9×42×-0.2×43.6×+3.6×
Price / book24.6×-5.2×26.2×-1.8×26.4×-1.3×28.3×+2.9×29.7×+6.7×
EV / EBITDA97.1×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Vertex Pharmaceuticals's profit margins?
Vertex Pharmaceuticals (VRTX) runs a 86.2% gross margin and a 38.3% operating margin, with a 35.5% net margin.
Where do Vertex Pharmaceuticals's ratios come from?
Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.